Cross-reactivity

Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Infection, Private Securities Litigation Reform Act, Founder, Society, Biology, FDA, Adult, Antibody-dependent enhancement, Annual report, Virology, HCV, Disease, SEC, SAD, Tropical medicine, Transactions of the Royal Society of Tropical Medicine and Hygiene, Dengue fever, ADE, Ageing, Food, World, Degenerative disease, MAD, GLOBE, Dengue virus, Fever Dream, Plasma, Patient, Pharmacokinetics, Federal Food, Drug, and Cosmetic Act, Doctor of Philosophy, Virus, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, World Health Organization, COVID-19, Annual general meeting, Respiratory syncytial virus, Severe acute respiratory syndrome coronavirus 2, RNA, Atea, RSV, Biochemistry, Safety, Poster, Nasdaq, NDA, Cross-reactivity, Tourism, Risk, PK, Pharmaceutical industry, Vaccine

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented a poster highlighting favorable AT-752 Phase 1 clinical data for the treatment of dengue fever at the American Society of Tropical Medicine & Hygiene (ASTMH) 2022 Annual Meeting in Seattle, Washington.

Key Points: 
  • Based on these data, we anticipate that AT-752 may have the potential to rapidly inhibit dengue virus replication across all serotypes (1-5).
  • The first study is a global, randomized, double-blind, placebo-controlled Phase 2 trial in adult patients with dengue virus infection.
  • AT-752, a novel, orally administered direct-acting antiviral derived from Ateas purine nucleotide prodrug platform was designed for the treatment and prophylaxis of dengue.
  • The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AT-752 for the treatment of dengue virus infection.

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

Retrieved on: 
Monday, September 26, 2022
Adult, Hospital, Atea, HCV, Safety, Trial of the century, Infection, COVID-19, Antibody-dependent enhancement, Federal Food, Drug, and Cosmetic Act, Risk, MD, FDA, Food, Disease, Virology, Virus, World, World Health Organization, List of islands in the Pacific Ocean, Severe acute respiratory syndrome coronavirus 2, Fever Dream, ADE, Review, Private Securities Litigation Reform Act, Respiratory syncytial virus, NDA, Dengue virus, Degenerative disease, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RSV, Viral disease, Biology, Public health, Annual report, Nasdaq, Biochemistry, Founder, Doctor of Philosophy, RNA, Fast Track, New Drug Application, Cross-reactivity, Pharmacokinetics, GLOBE, Fever, SEC, Mortality, Tourism, Vaccine, Pharmaceutical industry, Dengue fever

BOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AT-752, a novel, orally administered, direct-acting antiviral for the treatment of dengue virus infection.

Key Points: 
  • AT-752, a novel, orally administered direct-acting antiviral derived from Ateas purine nucleotide prodrug platform was designed for the treatment and prophylaxis of dengue.
  • Dengue is the most prevalent mosquito-borne virus affecting up to 400 million people annually and is a substantial public health and economic burden worldwide.
  • Dengue causes a severe generalized illness with fever which may require hospitalization and is associated with mortality.
  • The FDA, together with other governmental and non-governmental agencies, recognize dengue as a substantial and growing global public health burden.

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses

Retrieved on: 
Tuesday, August 24, 2021
Founder, Degenerative disease, SEC, RSV, Infection, RNA, Safety, Volunteering, Risk, WHO, Immunity, Severe acute respiratory syndrome coronavirus 2, Center, SAD, Human, Virus, Survival, Dengue fever, Fever Dream, Doctor of Philosophy, Viremia, Death, Therapy, Biology, Clinical trial, Disease, Biochemistry, Atea, Flavivirus, Dengue virus, Incidence, Pharmacokinetics, CDC, Tissue, Nasdaq, American Samoa, Journal, World, Mortality, Antibody-dependent enhancement, Antimicrobial, HCV, Private Securities Litigation Reform Act, GLOBE, NS5, World Health Organization, Patient, ADE, Cross-reactivity, COVID-19, Virology, Pharmaceutical industry, Vaccine

The article titled, Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses, can be accessed here .

Key Points: 
  • The article titled, Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses, can be accessed here .
  • The published data demonstratethat AT-752 has potent in vitro activity against multiple dengue virus serotypes and other flaviviruses tested, and reduces viremia and improves survival in an animal model ofdengue disease.
  • AT-752, an oral direct-acting antiviral, targets the non-structural protein 5 (NS5) polymerase of dengue virus.
  • Atea recently completedthe single ascending dose (SAD) portion ofaPhase 1aclinical trial of AT-752 and the multiple ascending dose portion is currently underway.

Atreca Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Antibody, Glycoproteins, Immunology, Clinical medicine, Medicine, Cross-reactivity, Toxicology, DLT, Dose

Atreca has completed enrollment in the fourth cohort (10 mg/kg) of the dose escalation portion of the trial, and all patients treated at that dose have now completed the 21 day dose-limiting toxicity (DLT) assessment period.

Key Points: 
  • Atreca has completed enrollment in the fourth cohort (10 mg/kg) of the dose escalation portion of the trial, and all patients treated at that dose have now completed the 21 day dose-limiting toxicity (DLT) assessment period.
  • No DLTs have been observed in the trial.
  • A human normal tissue cross-reactivity study showed no reactivity of toxicological significance, and APN-122597 is active in vitro in multiple formats.
  • These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101.

Integral Molecular Provides Rapid Safety Testing of COVID-19 Antibody Therapeutics with its Membrane Proteome Array Technology

Retrieved on: 
Friday, June 12, 2020
Branches of biology, Immunology, Biology, Immune system, Glycoproteins, Cross-reactivity, Antibodies

PHILADELPHIA, June 12, 2020 /PRNewswire/ -- Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.

Key Points: 
  • PHILADELPHIA, June 12, 2020 /PRNewswire/ -- Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.
  • "Off-target antibody binding can induce serious adverse clinical events," said Dimiter Dimitrov, PhD, ScD, CSO of Abound Bio.
  • "For this high-priority project, we relied on Integral Molecular's rapid specificity profiling to rule out liabilities arising from unexpected antibody cross-reactivity in human cells."
  • The MPA is a collection of 6,000 membrane proteins expressed in live cells, representing nearly the entire human membrane proteome.

Bio-Rad Begins Shipping SARS-COV-2 (COVID-19) Antibody Test That Offers More Than 99 Percent Specificity and 98 Percent Sensitivity

Retrieved on: 
Tuesday, April 21, 2020
Health, Infectious diseases, Hospitals, Clinical trials, Research, Science, Branches of biology, Viruses, Medical specialties, Glycoproteins, Zoonoses, Severe acute respiratory syndrome-related coronavirus, Animal virology, Antibody, Severe acute respiratory syndrome, Cross-reactivity, Coronavirus, Immunoglobulin G

Bio-Rads SARS-CoV-2 Total Ab test can help clinicians identify if an individual has been infected by SARS-CoV-2 and therefore has developed an immune response against the virus.

Key Points: 
  • Bio-Rads SARS-CoV-2 Total Ab test can help clinicians identify if an individual has been infected by SARS-CoV-2 and therefore has developed an immune response against the virus.
  • The test detects IgG, IgM, and IgA antibodies, an approach that appears to be more sensitive than assays against a single immunoglobulin1.
  • Clinical evaluation of the SARS-CoV-2 Total Ab test has demonstrated diagnostic specificity of more than 99 percent and diagnostic sensitivity of 98 percent.
  • Cross-reactivity testing demonstrated specificity of 100 percent with no reactivity against other interfering specimens including non-CoV-2 coronaviruses.

Muscle Protein That Prompts Allergic Reactions to Invertebrates May Also Cause Allergic Reactions to Fish

Retrieved on: 
Friday, March 20, 2020
Medical specialties, Medicine, Immune system, Immunology, Allergology, RTT, Antibodies, Immunoglobulin E, Allergy, Parvalbumin, Allergen, Cross-reactivity

To determine both the amount of IgE and the IgE cross-reactivity, the protein extracts of 66 fish species were analyzed for their allergen content.

Key Points: 
  • To determine both the amount of IgE and the IgE cross-reactivity, the protein extracts of 66 fish species were analyzed for their allergen content.
  • Additionally, the serum IgE reactivity in 80 children and 12 adults with fish allergies was compared to 12 common fish such as cod, tuna, and salmon.
  • The IgE reactivity levels of tropomyosin was second only to parvalbumin, a calcium-binding protein which at this time is the only recognized major fish allergen.
  • "More work must be done to examine the clinical relevance and cross-reactivity between vertebrates and invertebrates when it comes to tropomyosin."

AbCellera Announces the Issuance of Foundational Patent Claims Around Microfluidic Screening Assays for Antibody Discovery

Retrieved on: 
Thursday, November 7, 2019
Oncology, Health, Stem cells, Research, Pharmaceutical, Science, Branches of biology, Immune system, Immunology, Natural sciences, Biology, Antibody, Monoclonal antibody, Assay, Cross-reactivity, Phage display

AbCellera Biologics Inc., a global leader in therapeutic antibody discovery from natural immune systems, today announced that the U.S. Patent and Trademark Office (USPTO) has granted patent no.

Key Points: 
  • AbCellera Biologics Inc., a global leader in therapeutic antibody discovery from natural immune systems, today announced that the U.S. Patent and Trademark Office (USPTO) has granted patent no.
  • View the full release here: https://www.businesswire.com/news/home/20191107005276/en/
    Examples of AbCellera's proprietary single-cell assays (Graphic: Business Wire)
    The issuance of this patent further solidifies AbCelleras position as the innovation leader in next-generation antibody discovery.
  • Our patent portfolio includes broad and foundational claims on the use of microfluidics for high-throughput single-cell secretion assays, with application to antibody discovery and clone selection.
  • These include assays such as live-cell binding, specificity, cross-reactivity, affinity, receptor blocking and function, with applications in antibody discovery, antibody engineering, and cell line selection.

Beroni Group to Launch its Advanced US FDA-Approved Virus Diagnostic Kit to Help Combat Global Outbreaks of Zika, Dengue, Chikungunya and West Nile Viruses

Retrieved on: 
Thursday, October 24, 2019
Natural sciences, Physical sciences, Branches of biology, Laboratory techniques, Molecular biology, Polymerase chain reaction, Flaviviruses, Biotechnology, Reverse transcription polymerase chain reaction, Antibody, Cross-reactivity, Virus

Due to antibody cross-reactivity, each kit is usually only capable of separating a single virus.

Key Points: 
  • Due to antibody cross-reactivity, each kit is usually only capable of separating a single virus.
  • In comparison with other RT-PCT products, the CII-ArboViroPlex rRT-PCR assay has the following advantages:
    It can detect and differentiate four viruses ZIKV, DENGV, CHIKV, WNV without interference.
  • Beroni Group is an international biotechnological company listed on the National Stock Exchange of Australia and on the OTC markets in the USA.
  • Beroni Groups overall strategic goal is to become a worlds leading enterprise in the biotechnology, life sciences and environmental science industries.

New Blood Test Helps Clinicians Identify Potentially Life-threatening Ara h 6 Peanut Sensitization

Retrieved on: 
Tuesday, January 22, 2019
Medical specialties, Medicine, Immunology, Immune system, Allergology, RTT, Allergy, Immunoglobulin E, Cross-reactivity, Allergen, Radioallergosorbent test, Hycor Biomedical, Inc.

Thermo Fisher's ImmunoCAP Specific IgE blood test for Ara h 6, part of a line of assays for detecting specific peanut allergen components, has been cleared by the U.S. Food & Drug Administration for in vitro diagnostic use.

Key Points: 
  • Thermo Fisher's ImmunoCAP Specific IgE blood test for Ara h 6, part of a line of assays for detecting specific peanut allergen components, has been cleared by the U.S. Food & Drug Administration for in vitro diagnostic use.
  • Results from Ara h 6 ImmunoCAP testing can act as an aid to help specialists and other clinicians better understand patients' risk factors as part of tailored allergy treatment or management plans.
  • "Adding the Ara h 6 test to the existing ImmunoCAP peanut component assays enables us to provide a more complete view of a patient's overall peanut sensitization, including whether a patient is at risk for cross-reactivity."
  • ImmunoCAP blood testing is the most widely used specific IgE blood test, and its accuracy has been documented in more than 4,000 peer-reviewed publications.